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Rivaroxaban is a direct factor Xa inhibitor currently licensed for the acute treatment and prevention of venous thromboembolism and for the prevention of stroke in the context of atrial fibrillation (AF). We report our experience of administering rivaroxaban via a PEG tube in three patients requiring oral anticoagulation therapy, following a cardioembolic stroke (table 1) . A direct oral anticoagulant was selected over warfarin in order to reduce the need for regular INR testing in the community and as part of a local initiative to decrease district nursing workload. [3] compared to a whole tablet ingested is achieved. However, a report from Japan, where licensed doses of rivaroxaban are lower than those recommended elsewhere world-wide, reports that Japanese stroke patients receiving crushed rivaroxaban tablets had significantly lower rivaroxaban concentrations, than those stroke patients receiving the whole tablets at the equivalent dose [Okata et al., 2014] .
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When tablets are crushed, there is always the possibility that some may be lost in the crushing device, adsorbed to the feeding tube and lost in its transfer from the crushing device to the feeding tube.
Furthermore, rivaroxaban has poor water solubility and does not easily suspend in water, therefore making a suitable liquid preparation on the ward environment would be challenging. Our limited experience and that from Japan does suggests that significantly lower rivaroxaban concentrations are observed, when tablets are crushed and administered by a feeding tube in clinical practice and it would be sensible to assay rivaroxaban plasma concentrations when used in scenarios like this.
Other direct oral anticoagulants, whose absorption is not dependent on food, may result in adequate plasma concentrations. . Indeed apixaban's absorption is not dependent on food and apixaban's manufacturers suggest that following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of water and delivered via a nasogastric tube, exposure is similar to exposure seen in clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose [SPC, 2016] .
Switching from rivaroxaban to apixaban was the course of action taken in 2 of the 3 cases presented here, with an apixaban plasma concentration being measured in 1 patient and found to be adequate.
Edoxaban has also shown similar exposure to that seen in healthy subjects receiving a single 60mg In conclusion, if rivaroxaban is administered via a gastric tube, it would be prudent to measure plasma concentrations to ensure adequate exposure is being achieved. It may be possible to achieve adequate rivaroxaban plasma concentrations when administered via gastric tube providing the rivaroxaban SPC instructions are followed to the letter. As our experience has shown this may be difficult to achieve in clinical practice. If adequate DOAC concentrations are not achieved through A C C E P T E D M A N U S C R I P T [4] crushing process, then a vitamin K antagonist like warfarin with INR monitoring does remain a suitable option.
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